In 2004, lawyers for the GPS Industry Council again urged the FCC, in a letter, to approve proposed limits on terrestrial emissions that it had negotiated with Mobile Satellite Ventures.
The FDA had initially declined to approve Zioptan, sending Merck a "complete response" letter in November asking for more information about the new drug application.